Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has earned a consensus rating of “Hold” from the twenty-one research firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $53.42.
Several research analysts recently commented on the company. Jefferies Group LLC reiterated a “buy” rating and issued a $59.00 price target on shares of Pacira Pharmaceuticals in a research report on Thursday, September 7th. Wedbush reiterated an “outperform” rating and issued a $87.00 price target on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 19th. Canaccord Genuity reiterated a “buy” rating and issued a $56.00 price target on shares of Pacira Pharmaceuticals in a research report on Monday, July 31st. Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Mizuho reissued a “buy” rating and issued a $53.00 price objective (down previously from $54.00) on shares of Pacira Pharmaceuticals in a research note on Tuesday, August 22nd.
In related news, Director Paul J. Hastings sold 1,044 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total value of $37,740.60. Following the completion of the transaction, the director now owns 3,518 shares of the company’s stock, valued at $127,175.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Kristen Marie Williams sold 3,461 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total transaction of $127,191.75. Following the completion of the transaction, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at approximately $783,216. The disclosure for this sale can be found here. Insiders have sold 33,390 shares of company stock valued at $1,215,480 in the last ninety days. Insiders own 6.60% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Baillie Gifford & Co. grew its holdings in Pacira Pharmaceuticals by 40.9% in the second quarter. Baillie Gifford & Co. now owns 301,000 shares of the company’s stock worth $14,358,000 after purchasing an additional 87,400 shares during the last quarter. Highbridge Capital Management LLC purchased a new position in Pacira Pharmaceuticals in the first quarter worth $3,648,000. Stephens Inc. AR grew its holdings in Pacira Pharmaceuticals by 8.0% in the first quarter. Stephens Inc. AR now owns 24,676 shares of the company’s stock worth $1,125,000 after purchasing an additional 1,835 shares during the last quarter. FNY Partners Fund LP purchased a new position in Pacira Pharmaceuticals in the first quarter worth $136,000. Finally, Sei Investments Co. grew its holdings in Pacira Pharmaceuticals by 75.2% in the second quarter. Sei Investments Co. now owns 40,495 shares of the company’s stock worth $1,932,000 after purchasing an additional 17,388 shares during the last quarter.
Pacira Pharmaceuticals (NASDAQ PCRX) traded down 1.65% on Friday, reaching $35.70. The company’s stock had a trading volume of 602,258 shares. Pacira Pharmaceuticals has a one year low of $29.95 and a one year high of $58.95. The company’s market capitalization is $1.44 billion. The firm has a 50-day moving average of $36.91 and a 200-day moving average of $44.24.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.06). The company had revenue of $70.90 million during the quarter, compared to analysts’ expectations of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The company’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.21 EPS. Analysts predict that Pacira Pharmaceuticals will post ($0.17) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Analysts Set Pacira Pharmaceuticals, Inc. (PCRX) Price Target at $53.42” was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://transcriptdaily.com/2017/09/20/analysts-set-pacira-pharmaceuticals-inc-pcrx-price-target-at-53-42.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.